Business Standard

Jubilant Life gains on ANDA approval for generic drug

The stock was up 3.4% at Rs 961 in intra-day trade, extending its past two days 3% gain on BSE.

Jubilant DraxImage facility
Premium

Jubilant DraxImage facility

SI Reporter Mumbai
Jubilant Life Sciences was up 3.4% at Rs 961, extending its 3% gain in past two days on BSE, after the company announced that it has received Abbreviated New Drug Application (ANDA) approval for Clonidine Hydrochloride Extended-Release Tablets.

“Jubilant Pharma, a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg, the generic version of Kapvay® of Concordia,” Jubilant Life Sciences said in a press release.

Concordia is used for the treatment of attention deficit hyperactivity disorder (ADHD) as

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 31 2018 | 9:57 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com